Management Committee of the Board of Directors of the Company in their meeting held today have allotted 1,50,830 equity shares of face value of Rs. 10/- each to M/s. Karuna Business Solutions LLP (Warrant Holder) upon conversion of equivalent number of warrants to equity shares.
These shares shall rank in pari passu with the existing equity shares of the Company in all respects.
Consequent to above, the paid-up share capital of the Company has increased from Rs. 90,13,93,740 consisting of 9,01,39,374 equity shares of Rs. 10/- each to Rs. 90,29,02,040 consisting of 9,02,90,204 equity shares of Rs. 10/- each.
Request you to take the above on record.
Thanks & Regards,
For Strides Pharma Science Limited,
MANJULA RAMAMU RTHY
Digitally signed by MANJULA RAMAMURTHY Date: 2022.09.16 15:14:58 +05'30'
Manjula R Company Secretary
Attachments
Original Link
Original Document
Permalink
Disclaimer
Strides Pharma Science Ltd. published this content on 16 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 September 2022 10:49:08 UTC.
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche and pharmaceutical products. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.